Q-omics provides the consensus-scored RBBP4P2 profile across patient tissues and cancer cell-line models. RBBP4P2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RBBP4P2 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, RBBP4P2 RNA expression shows 18,663 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where RBBP4P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBBP4P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBBP4P2 survival associations across molecular data types. RBBP4P2 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBBP4P2 RNA expression–survival associations across cancer types. High RBBP4P2 expression shows unfavorable associations in LGG, MESO and SARC, but favorable associations in ACC, COAD and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for RBBP4P2 RNA expression.
This table summarizes RBBP4P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RBBP4P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBBP4P2 shows lower tumor expression in KICH and higher tumor expression in HNSC, STAD, BLCA, LIHC and LUSC. The HNSC box plot shows higher RBBP4P2 RNA expression in tumor versus normal tissue (log2 FC = +0.102, t-test p = .002).
This table shows molecular features associated with RBBP4P2 in patient tissues and cancer cell lines. In patient samples, RBBP4P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
